lymphoma Archives -

A history of blood cancer treatment

Eloise McLennan A history of..., blood cancer, bone marrow transplant, breakthroughs, CAR-T therapies, cell therapies, chemotherapy, cord blood, immunology, leukaemia, lymphoma, melanoma, Non-Hodgkins Lymphoma 0 Comment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to

A history of blood cancer treatment

https://pharmaphorum.com/oncology/a-history-of-blood-cancer-treatment/

News/ News/ News/ Oncology/ R&D

Nkarta leaps on early CAR-NK data in blood cancers

Phil Taylor acute myeloid leukaemia, car-nk, cell therapy, Haematology, immuno-oncology, lymphoma, Nkarta, Oncology 0 Comment

Shares in Nkarta more than doubled yesterday on the results of early-stage clinical that suggested it could be

Nkarta leaps on early CAR-NK data in blood cancers

https://pharmaphorum.com/news/nkarta-leaps-on-early-car-nk-data-in-blood-cancers/

News/ News/ News/ Oncology/ R&D

Implants could transform CAR-T therapy into one-day procedure

Phil Taylor bioengineering, CAR-T therapies, immuno-oncology, lymphoma, Oncology, R&D 0 Comment

CAR-T therapies have revolutionised the treatment of some blood cancers, but are costly as well as time- and

Implants could transform CAR-T therapy into one-day procedure

https://pharmaphorum.com/news/implants-could-transform-car-t-therapy-into-one-day-procedure/

News/ News/ News/ Oncology/ R&D

Genmab and AbbVie prep filings for lymphoma bispecific

Phil Taylor AbbVie, epcoritamab, Genmab, immuno-oncology, lymphoma, Oncology, partnering 0 Comment

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said

Genmab and AbbVie prep filings for lymphoma bispecific

https://pharmaphorum.com/news/abbvie-preps-filings-for-lymphoma-bispecific-licensed-from-genmab/

News/ News/ Oncology

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

Phil Taylor Breyanzi, Bristol-Myers Squibb, CAR-T therapies, Gilead Sciences, lymphoma, Oncology, regulatory approval, Yescarta 0 Comment

Gilead Sciences’ Kite Pharma has become the first drugmaker to get FDA approval to use a CAR-T therapy

Gilead beats BMS to FDA okay for early lymphoma CAR-T therapy

https://pharmaphorum.com/news/gilead-beats-bms-to-fda-okay-for-early-lymphoma-car-t-therapy/

News/ News/ R&D

Equillium triples clinical pipeline with $329m Bioniz takeover

Phil Taylor alopecia, Bioniz, coeliac disease, Equillium, graft versus host disease, immunology, lymphoma, M&A 0 Comment

Equillium has announced another bolt-on deal to expand its pipeline tripling the size of its clinical pipeline to

Equillium triples clinical pipeline with $329m Bioniz takeover

https://pharmaphorum.com/news/equillium-triples-clinical-pipeline-with-329m-bioniz-takeover/

News/ News/ Oncology

NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo

Phil Taylor HEOR, Kyowa Kirin, lymphoma, NHS, NICE, Oncology, Poteligeo 0 Comment

NICE has reversed an earlier decision not to recommend NHS use of Kyowa Kirin’s Poteligeo for two rare

NICE changes tack on ‘game changer’ rare cancer therapy Poteligeo

https://pharmaphorum.com/news/nice-changes-tack-on-game-changer-rare-cancer-therapy-poteligeo/

News/ News/ Oncology

FDA halts Allogene CAR-T trial after safety scare

Phil Taylor Allogene, CAR T, cell therapy, immuno-oncology, lymphoma, Oncology, safety 0 Comment

A phase 1 trial of Allogene’s of-the-shelf CAR-T for lymphoma has been placed on hold by the FDA,

FDA halts Allogene CAR-T trial after safety scare

https://pharmaphorum.com/news/fda-halts-allogene-car-t-trial-after-safety-scare/

News/ News/ Oncology

Failed trial nixes another FDA approval, this time for BMS’ Istodax

Phil Taylor Bristol-Myers Squibb, fda, Istodax, lymphoma, Oncology 0 Comment

Bristol-Myers Squibb’s HDAC inhibitor Istodax has been on the US market for a decade as a treatment for

Failed trial nixes another FDA approval, this time for BMS’ Istodax

https://pharmaphorum.com/news/failed-trial-nixes-another-fda-approval-this-time-for-bms-istodax/

Trending

lymphoma

Login